Targeting the E3 ubiquitin casitas B‐lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis
暂无分享,去创建一个
A. Patiño-García | F. Lecanda | O. Fromigué | P. Marie | N. Severe | C. Marty | D. Modrowski | François‐Xavier Dieudonné
[1] A. Weissman,et al. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis , 2011, Nature Reviews Cancer.
[2] P. Marie,et al. The Casitas B Lineage Lymphoma (Cbl) Mutant G306E Enhances Osteogenic Differentiation in Human Mesenchymal Stromal Cells in Part by Decreased Cbl-mediated Platelet-derived Growth Factor Receptor α and Fibroblast Growth Factor Receptor 2 Ubiquitination* , 2011, The Journal of Biological Chemistry.
[3] Peter F. M. Choong,et al. The Molecular Pathogenesis of Osteosarcoma: A Review , 2011, Sarcoma.
[4] James Lowe,et al. Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets , 2010, Nature Reviews Drug Discovery.
[5] M. Nau,et al. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. , 2010, Cancer Research.
[6] J. Ringe,et al. Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. , 2010, Human Molecular Genetics.
[7] M. Loh,et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.
[8] S. Ogawa,et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.
[9] T. Hunter. Tyrosine phosphorylation: thirty years and counting. , 2009, Current opinion in cell biology.
[10] O. Fromigué,et al. Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell Invasion* , 2008, Journal of Biological Chemistry.
[11] A. Sanjay,et al. FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival. , 2008, Bone.
[12] O. Fromigué,et al. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. , 2007, Cancer research.
[13] C. Dufour,et al. Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation. , 2006, The American journal of pathology.
[14] A. Tsygankov,et al. The Cbl family proteins: Ring leaders in regulation of cell signaling , 2006, Journal of cellular physiology.
[15] J. Wade Harper,et al. Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.
[16] N. Ishimaru,et al. Ubiquitin Ligase Cbl‐b Downregulates Bone Formation Through Suppression of IGF‐I Signaling in Osteoblasts During Denervation , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] P. Auberger,et al. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation , 2006, Cell Death and Differentiation.
[18] M. Nau,et al. Regulating the regulator: negative regulation of Cbl ubiquitin ligases. , 2006, Trends in biochemical sciences.
[19] Ivan Dikic,et al. The Cbl interactome and its functions , 2005, Nature Reviews Molecular Cell Biology.
[20] I. Rose. Ubiquitin at Fox Chase* , 2005, Cell Death and Differentiation.
[21] A. Ciechanover. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin–proteasome system and onto human diseases and drug targeting* , 2005, Cell Death and Differentiation.
[22] P. Marie,et al. Cbl-mediated ubiquitination of α5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation , 2005, Journal of Cell Science.
[23] J. Lemonnier,et al. Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation* , 2004, Journal of Biological Chemistry.
[24] Morag Park,et al. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. , 2003, Cancer cell.
[25] Ivan Dikic,et al. Negative receptor signalling. , 2003, Current opinion in cell biology.
[26] Y. Yarden,et al. The role of ubiquitylation in signaling by growth factors: implications to cancer. , 2003, Seminars in cancer biology.
[27] L. Penengo,et al. Receptor tyrosine kinases as target for anti-cancer therapy. , 2002, Current pharmaceutical design.
[28] H. Ding,et al. Induction of apoptosis in cancer: new therapeutic opportunities , 2002, Annals of medicine.
[29] A. Tsygankov,et al. Beyond the RING: CBL proteins as multivalent adapters , 2001, Oncogene.
[30] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[31] P. Meltzer,et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. , 2001, Cancer research.
[32] W. Langdon,et al. Cbl: many adaptations to regulate protein tyrosine kinases , 2001, Nature Reviews Molecular Cell Biology.
[33] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[34] J. Lemonnier,et al. N‐ and E‐cadherin mediate early human calvaria osteoblast differentiation promoted by bone morphogenetic protein‐2 , 2000 .
[35] Y. Yarden,et al. The RING Finger of c-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor* , 1999, The Journal of Biological Chemistry.
[36] Z. Kam,et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.
[37] B. Himelstein. Osteosarcoma and other bone cancers. , 1998, Current opinion in oncology.
[38] H. Band,et al. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity , 1997, Molecular and cellular biology.
[39] T. O'Brien,et al. Therapeutic strategies within the ubiquitin proteasome system , 2010, Cell Death and Differentiation.
[40] A. Ciechanover,et al. The ubiquitin proteasome system and its involvement in cell death pathways , 2010, Cell Death and Differentiation.
[41] N. Jaffe. Osteosarcoma: review of the past, impact on the future. The American experience. , 2009, Cancer treatment and research.
[42] L. Helman,et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential , 2004, Clinical & Experimental Metastasis.